{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:07:24Z","timestamp":1790863644225,"version":"4.1.0"},"reference-count":17,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionised the management of advanced malignancies, but can cause immune-related adverse events (irAEs), including vision-threatening complications such as optic neuropathy. Ocular irAEs have been described with several programmed death-1\/programmed death-ligand 1 and cytotoxic T lymphocyte-associated antigen-4 inhibitors, but ocular toxicities of tislelizumab have so far been limited to Vogt-Koyanagi-Harada (VKH)-like uveitis, panuveitis and retinal vasculitis. We describe a woman with metastatic lung adenocarcinoma who was treated with second-line gemcitabine, carboplatin and tislelizumab. After the second cycle of chemo-immunotherapy, she developed painless, progressive bilateral visual blurring in the absence of intracranial disease. Ophthalmic assessment was consistent with toxic optic neuropathy in the context of ongoing tislelizumab exposure, and other causes were excluded. Tislelizumab was discontinued and high-dose intravenous methylprednisolone (1\u2009g\/day for 5\u2009days) was administered, without ICI re-challenge. Visual function did not improve, indicating an irreversible optic nerve injury. To our knowledge, this is the first reported case of toxic optic neuropathy associated with tislelizumab, extending the spectrum of tislelizumab-related ocular irAEs beyond previously documented VKH-like panuveitis, VKH-like uveitis and retinal vasculitis. This case highlights the importance of early recognition of visual symptoms and periodic ophthalmic assessment in patients receiving ICIs, as well as decision-making regarding ICI continuation or discontinuation when sight-threatening neuro-ophthalmic irAEs are suspected.<\/jats:p>","DOI":"10.1136\/bcr-2026-276747","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:43:38Z","timestamp":1790862218000},"page":"e276747","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Presentation and management of tislelizumab induced toxic optic neuropathy"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3078-9185","authenticated-orcid":false,"given":"Souvik","family":"Mondal","sequence":"first","affiliation":[{"name":"Radiation Oncology, AIIMS Bhubaneswar, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Barik","sequence":"additional","affiliation":[{"name":"Radiation Oncology, AIIMS Bhubaneswar, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakanksha","family":"Shaw","sequence":"additional","affiliation":[{"name":"Ophthalmology, AIIMS Bhubaneswar, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruttendu","family":"Moharana","sequence":"additional","affiliation":[{"name":"Ophthalmology, AIIMS Bhubaneswar, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100106251925000_19.10.e276747.1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer","volume":"4","author":"Dine","year":"2017","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2026100106251925000_19.10.e276747.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2026100106251925000_19.10.e276747.3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"Young","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026100106251925000_19.10.e276747.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.012"},{"key":"2026100106251925000_19.10.e276747.5","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/ijms26072907","article-title":"Reactive Astrocytes in Glioma: Emerging Opportunities and Challenges","volume":"26","author":"Wu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026100106251925000_19.10.e276747.6","doi-asserted-by":"crossref","first-page":"1044904","DOI":"10.3389\/fopht.2022.1044904","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions","volume":"2","author":"Winges","year":"2022","journal-title":"Front Ophthalmol"},{"key":"2026100106251925000_19.10.e276747.7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ajo.2024.08.044","article-title":"Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database","volume":"268","author":"Quiruz","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"2026100106251925000_19.10.e276747.8","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noad137.157","article-title":"P06.17.A optic neuropathy related to immune checkpoint inhibitors: A case series","volume":"25","author":"Cuzzubbo","year":"2023","journal-title":"Neuro-oncology"},{"key":"2026100106251925000_19.10.e276747.9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune Checkpoint Inhibitor-Associated Optic Neuritis","volume":"127","author":"Francis","year":"2020","journal-title":"Ophthalmology"},{"key":"2026100106251925000_19.10.e276747.10","doi-asserted-by":"crossref","unstructured":"Ding H , Zhang S , Lin L , et al . Case Report: Tislelizumab\u2013induced panuveitis: a report of two cases. Front Pharmacol 2025;16. doi:10.3389\/fphar.2025.1678663","DOI":"10.3389\/fphar.2025.1678663"},{"key":"2026100106251925000_19.10.e276747.11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026100106251925000_19.10.e276747.12","doi-asserted-by":"crossref","unstructured":"Rojas-Pineda E la , Cintas N , Bruix A , et al . Retinal Vasculitis Associated with Tislelizumab in a Patient with Esophageal Squamous Cell Carcinoma. Retin Cases Brief Rep 2025. doi:10.1097\/ICB.0000000000001817","DOI":"10.1097\/ICB.0000000000001817"},{"key":"2026100106251925000_19.10.e276747.13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12886-026-04743-7","article-title":"Tislelizumab-induced Vogt-Koyanagi-Harada-like uveitis: a case report","volume":"26","author":"Zhou","year":"2026","journal-title":"BMC Ophthalmol"},{"key":"2026100106251925000_19.10.e276747.14","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921992989","article-title":"Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm","volume":"13","author":"Shahzad","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2026100106251925000_19.10.e276747.15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011049","article-title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Chang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026100106251925000_19.10.e276747.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026100106251925000_19.10.e276747.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-276747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:43:41Z","timestamp":1790862221000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-276747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bcr-2026-276747"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-276747","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}